Table 4.
Proportion of visual acuity outcomes at 12 months
| VA loss < 5 letters or VA gain, n (%) | VA loss ≥ 5 letters, n (%) | VA loss ≥ 10 letters, n (%) | VA loss ≥ 15 letters, n (%) | VA ≤ 20/32 Snellen equivalent, n (%) | VA ≤ 20/40 Snellen equivalent, n (%) | |
|---|---|---|---|---|---|---|
| All eyes, n = 249 | 159 (63.9) | 90 (36.1) | 38 (15.3) | 17 (6.8) | 70 (28.1) | 30 (12.0) |
| All eyes observed over 12M, n = 94 | 69 (73.4) | 25 (26.6) | 8 (8.5) | 5 (5.3) | 20 (21.3) | 7 (7.4) |
| All eyes treated over 12M, n = 155 | 90 (58.1) | 65 (41.9) | 30 (19.4) | 12 (7.7) | 50 (32.3) | 23 (14.8) |
| All eyes observed over 12M with stable VA* within first 6M, n = 73 | 63 (86.3) | 10 (13.7) | 1 (1.4) | 0 (0) | 7 (9.6) | 1 (1.4) |
| Eyes observed and with VA loss ≥ 5 letters within 6M | ||||||
| Further observed, n = 21 | 6 (28.6) | 15 (71.4) | 7 (33.3) | 5 (23.8) | 13 (61.9) | 6 (28.6) |
| Treated, n = 33 | 17 (51.5) | 16 (48.5) | 6 (18.2) | 3 (9.1) | 12 (36.4) | 4 (12.1) |
| Eyes treated at baseline | ||||||
| 1–7 anti-VEGF injections, n = 63 | 34 (54.0) | 29 (46.0) | 17 (27.0) | 6 (9.5) | 24 (38.1) | 13 (20.6) |
| 8–12 anti-VEGF injections, n = 17 | 13 (76.5) | 4 (23.5) | 0 (0) | 0 (0) | 4 (23.5) | 0 (0) |
M months, VA visual acuity, VEGF vascular endothelial growth factor
*VA loss ≤ 4 letters or VA gain